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Abstract
IMPORTANCE The effect of polyvascular disease on cardiovascular outcomes in the background of
peripheral artery disease (PAD) is unclear.
OBJECTIVE To determine the risk of ischemic events (both cardiac and limb) among patients with
PAD and polyvascular disease.
DESIGN, SETTING, AND PARTICIPANTS In this post hoc secondary analysis of the international
Examining Use of Ticagrelor in Peripheral Artery Disease (EUCLID) trial, outcomes were compared
among 13 885 enrolled patients with PAD alone, PAD + coronary artery disease (CAD), PAD +
cerebrovascular disease (CVD), and PAD + CAD + CVD. Adjusted Cox proportional hazards regression
models were implemented to determine the risk associatedwith polyvascular disease and outcomes,
and intention-to-treat analysis was performed. The EUCLID trial was conducted fromDecember 31,
2012, to March 7, 2014; the present post hoc analysis was performed from June 1, 2017, to February
5, 2018.
INTERVENTIONS EUCLID evaluated ticagrelor vs clopidogrel in preventing major adverse cardiac
events (cardiovascular death, myocardial infarction [MI], or ischemic stroke) and major bleeding in
patients with PAD.
MAINOUTCOMES ANDMEASURES The primary end point was a composite of cardiovascular
death, MI, or ischemic stroke. Key secondary end points included the individual components of the
primary end point and acute limb ischemia leading to hospitalization, major amputation, and lower-
extremity revascularization. The primary end point of Thrombolysis in Myocardial Infarction (TIMI)
major bleeding was also evaluated.
RESULTS The EUCLID trial randomized 13 885 patients with a median age of 66 years (interquartile
range, 60-73 years), of whom 3888 (28.0%)were women. At baseline, 7804 patients (56.2%) had
PAD alone; 2639 (19.0%) had PAD + CAD; 2049 (14.8%) had PAD + CVD; and 1393 (10.0%) had PAD +
CAD + CVD. Compared with patients with isolated PAD, the adjusted hazard ratios (aHRs) for major
adverse cardiac events were 1.34 (95% CI, 1.15-1.57; P < .001) for PAD + CVD, 1.65 (95% CI, 1.43-1.91;
P < .001) for PAD + CAD, and 1.99 (95% CI, 1.69-2.34; P < .001) for PAD + CAD + CVD. The aHRs for
lower-extremity revascularization were 1.17 (95% CI, 1.03-1.34; P = .01) for PAD + CAD, 1.17 (95% CI,
1.02-1.35; P = .02) for PAD + CVD, and 1.34 (95% CI, 1.15-1.57; P < .001) for PAD + CAD + CVD.
Polyvascular disease was not associated with an increased risk of acute limb ischemia (aHR for PAD +
CVD, 0.91; 95%CI, 0.62-1.34, P = .63; PAD + CAD, 0.93; 95%CI, 0.64-1.34, P = .69; and PAD + CAD +
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Key Points
Question Does the presence of
polyvascular disease affect the risk of
ischemic events, both cardiac and limb,
and bleeding in patients with peripheral
artery disease?
Findings In this secondary analysis of a
randomized clinical trial of 13 885
patients with peripheral artery disease
randomized to receive ticagrelor or
clopidogrel comparedwith patients with
isolated peripheral artery disease, those
with concomitant peripheral artery
disease and polyvascular disease had an
increased risk of major adverse cardiac
events and lower-extremity
revascularization. Polyvascular disease
was not associated with an increased
risk of Thrombolysis in Myocardial
Infarctionmajor bleeding.
Meaning These data highlight the
increased risk of coronary artery disease
and cerebrovascular disease among
patients with peripheral artery disease
and the need to identify potent
preventive antithrombotic therapies.
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Abstract (continued)
CVD, 0.98; 95% CI, 0.63-1.53, P = .93), major amputation (aHR for PAD + CVD, 0.83; 95% CI, 0.54-
1.27, P = .40; PAD + CAD, 0.74; 95% CI, 0.47-1.16, P = .19; and PAD + CAD + CVD, 1.12; 95% CI, 0.69-
1.80, P = .65), or TIMI major bleeding (PAD + CVD, 0.98; 0.66-1.44, P = .91; PAD + CAD, 1.04; 0.74-
1.48, P = .81; and PAD + CAD + CVD, 0.96; 95% CI, 0.62-1.51, P = .88).
CONCLUSIONS ANDRELEVANCE Compared with patients with PAD alone, the risk of major
adverse cardiac events and lower-extremity revascularization increased with multiple vascular bed
involvement. There was no clear increased risk of bleeding associated with polyvascular disease.
JAMA Network Open. 2018;1(7):e185239. doi:10.1001/jamanetworkopen.2018.5239
Introduction
Patients with peripheral artery disease (PAD) are a high-risk population.1 Peripheral artery disease
enhances the risk of major adverse cardiac events (MACEs), defined as cardiovascular death,
myocardial infarction (MI), and ischemic stroke.2 Observational studies report that among patients
with PAD, the risk of cardiac events is greatest in those with concomitant coronary artery disease
(CAD) and/or cerebrovascular disease (CVD), a condition known as polyvascular disease.3 In addition
toMACEs, patients with PAD are also at risk formajor adverse limb events, which include but are not
limited to acute limb ischemia (ALI), major amputation, and lower-extremity revascularization.4
Antithrombotic strategies are considered the cornerstone therapy for preventing cardiovascular
events in patients with PAD.5 To date, studies evaluating the use of intense antithrombotic therapies
in patients with PAD have all demonstrated a heightened risk of bleeding with varying degrees of
efficacy in reducing both cardiac and limb events.6-10 Antithrombotic therapy in patients with PAD
can be particularly problematic as the same comorbidities conferring an increased risk for
atherothrombosis, such as older age, diabetes, and renal dysfunction, also predispose this
population to bleeding.11,12
In the Examining Use of Ticagrelor in Peripheral Artery Disease (EUCLID) trial, monotherapy
with ticagrelor compared with clopidogrel did not reduce the rates of MACEs in patients with
symptomatic PAD.13,14 Using the PAD study population from the EUCLID trial, the present study aims
to evaluate the association between polyvascular disease andMACEs as well as major adverse limb
events and determine the risk of bleeding associated with polyvascular disease.
Methods
Study Population
This is a post hoc secondary analysis of the EUCLID trial (ClinicalTrials.gov identifier: NCT01732822).
The study design and results of the EUCLID trial have been previously published.13,14 Briefly, EUCLIDwas
a double-blind, active-comparator trial of ticagrelor vs clopidogrel in patients with symptomatic PAD.
Between December 31, 2012, andMarch 7, 2014, patients with symptomatic PADwere randomized
in a 1:1 double-blindmanner via an interactive voice- or web-response system to receive ticagrelor, 90
mg twice daily, or clopidogrel, 75 mg once daily. Patients were followed up until May 9, 2016. On
screening, patientswere eligible if theywere aged 50 years or older and had symptomatic PAD, defined
as an ankle-brachial index of 0.80or less or lower-extremity revascularizationmore than 30days before
randomization. With regard to ankle-brachial index eligibility criteria, a confirmationmeasurement of
0.85 or lesswas also required at the time of randomization. In settings inwhich the ankle-brachial index
was 1.40 or greater at screening, a toe-brachial index cutoff level of 0.60 or lower was implemented,
with a required second reading of 0.65 or lower at randomization.
Exclusion criteria were as follows: (1) current or planned use of dual antiplatelet therapy; (2)
history of poor clopidogrel metabolism, defined as 2 loss-of-function cytochrome P450 enzyme
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2C19 allele variants; (3) need for long-term anticoagulation; and (4) elevated bleeding risk. In the
present study, patients were grouped according to baseline history of CAD or CVD in the following
manner: PAD alone, PAD + CAD, PAD + CVD, and PAD + CAD + CVD. History of CAD or CVDwas based
on clinical data obtained at the start of the trial. Prior CADwas defined on the case report form as a
history of percutaneous coronary intervention, coronary artery bypass grafting, or MI. Prior CVDwas
defined based on the case report form as a history of stroke or transient ischemic attack, carotid
stenosis, or carotid revascularization.
All patients provided written informed consent, and the trial protocol was reviewed and
approved by appropriate ethics committees at participating sites. The EUCLID publication
committee approved the post hoc analysis with waiver of informed consent.
End Points
The primary end point in the EUCLID trial was a composite of cardiovascular death, MI, or ischemic
stroke. For the present study, key secondary end points included the individual components of the
primary end point and ALI leading to hospitalization, major amputation, and lower-extremity
revascularization. The primary end point of Thrombolysis in Myocardial Infarction (TIMI) major
bleeding was also evaluated.
Statistical Analysis
The present analysis was conducted from June 1, 2017, to February 5, 2018. Continuous variables are
presented as medians with interquartile ranges and were assessed using the Kruskal-Wallis test.
Categorical variables are reported as counts and percentages and were assessed using χ2 tests. End
points were assessed according to the following groups: PAD alone (reference group), PAD + CAD,
PAD + CVD, and PAD + CAD + CVD. Analyses were performed according to the intention-to-treat
principle and included all randomized patients. The interaction between the number of diseased
vascular beds and treatment cohorts—ticagrelor or clopidogrel—for the primary end points was
assessed. A Cox proportional hazards regressionmodel was applied to determine the association
between polyvascular disease and outcomes. Results of the models include adjusted hazard ratios
(aHRs), 95% CIs, and P values.
Adjustment variables for each outcomewere chosen using a stepwise selection process with α
level = .05. Results for the primary composite efficacy end point were adjusted for age, weight, sex,
estimated glomerular filtration rate, baseline ankle-brachial index, randomized treatment, inclusion
criteria, critical limb ischemia, diabetes (type 1 or 2), statin use before randomization, smoking status,
prior major amputation, and prior minor amputation. Cardiovascular death was adjusted for age,
weight, estimated glomerular filtration rate, baseline ankle-brachial index, randomized treatment,
sex, geographic region, critical limb ischemia, diabetes, use of statins before randomization, and prior
minor amputation. Myocardial infarction was adjusted for age, estimated glomerular filtration rate,
baseline ankle-brachial index, randomized treatment, inclusion criteria, geographic region, diabetes,
smoking status, and prior minor amputation. Ischemic stroke was adjusted for age, baseline ankle-
brachial index, randomized treatment, geographic region, diabetes, smoking status, and prior minor
amputation.
For safety events, the results for the primary safety end point were adjusted for age,
randomized treatment, and geographic region. Acute limb ischemia was adjusted for baseline ankle-
brachial index, randomized treatment, inclusion criteria, use of statins before randomization, and
use of angiotensin receptor blockers before randomization. Lower-extremity revascularization was
adjusted for baseline ankle-brachial index, estimated glomerular filtration rate, inclusion criteria,
diabetes, use of aspirin before randomization, use of clopidogrel before randomization, and smoking
status. Amputation was adjusted for weight, baseline ankle-brachial index, inclusion criteria, critical
limb ischemia, diabetes, use of statins before randomization, priormajor amputation, and priorminor
amputation. Major bleeding was adjusted for age, randomized treatment, and geographic region.
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The proportional hazards assumption was evaluated using weighted Schoenfeld residuals, and
there were no major violations of the assumption for any outcome. Kaplan-Meier curves are
presented for the composite end point of cardiovascular death, MI, or ischemic stroke according to
polyvascular disease phenotype. The P value for the log-rank test is presented on each plot.
Two-sided P values.05 were considered statistically significant.
All statistical analyses were performed by the Duke Clinical Research Institute (Duke University
School of Medicine, Durham, NC), using SAS, version 9.4 (SAS Institute Inc).
Results
Patients
The EUCLID trial screened 16 237 patients with symptomatic PAD. After implementing inclusion and
exclusion criteria, 13 885 patients, of whom 3888 (28.0%) were women, with a median age of 66
years (interquartile range, 60-73 years) underwent randomization. Polyvascular disease was present
in 43.8%of the patients: 7804 patients (56.2%) had PAD alone, 2639 (19.0%) had PAD + CAD, 2049
(14.8%) had PAD + CVD, and 1393 (10.0%) had PAD + CAD + CVD.Most randomized patients (56.7%)
met inclusion criteria owing to a history of lower-extremity revascularization.
Compared with patients with PAD alone, those with polyvascular disease were older; more
likely to have multiple comorbidities, such as diabetes, hypertension, or hyperlipidemia; and more
likely to have undergone prior lower-extremity revascularization (Table 1).
Before randomization, patients with polyvascular disease were more frequently treated with
aspirin, clopidogrel, dual antiplatelet therapy, angiotensin-converting enzyme inhibitors, or
angiotensin receptor blockers. In contrast, patients with PAD alone weremore frequently treated
with cilostazol (Table 1).
Outcomes
The rate of the primary end point of the composite of cardiovascular death, MI, or ischemic stroke,
defined as events per 100 patient-years, was greatest in patients with polyvascular disease, with the
lowest event rates occurring in patients with PAD alone (3.4), followed by PAD + CVD (4.8), PAD +
CAD (5.7), and PAD + CAD + CVD (8.1) (log-rank P < .001) (Table 2 and Figure 1A). Rates for the
individual components of cardiovascular death andMI increased in a similar incremental fashion with
each additional diseased vascular bed. Rates for ischemic stroke were heightened only among
patients with CVD—those with PAD + CVD or PAD + CAD + CVD. Figure 1B, C, and D depict the
36-month Kaplan-Meier rates for the individual components of the primary composite end point
(cardiovascular death, MI, and ischemic stroke, respectively) according to vascular disease
phenotype. There was no significant difference in rates of ALI requiring hospitalization andmajor
amputation among patients with polyvascular disease compared with patients with PAD alone.
The rate of lower-extremity revascularization increased per 100 patient-years with each
additional diseased vascular bed, with the lowest rates in patients with PAD alone (4.8), followed by
PAD + CVD (5.9), PAD + CAD (6.0), and PAD + CAD + CVD (7.6) (log-rank P < .001). The rate of TIMI
major bleeding, defined as events per 100 patient-years, was similar among all 4 cohorts: PAD alone
(0.70); PAD + CVD (0.76); PAD + CAD (0.84); and PAD + CAD + CVD (0.89) (log-rank P = .58)
(Table 2). The ticagrelor vs clopidogrel comparison among all of the polyvascular disease subgroups
(PAD + CAD, PAD + CVD, and PAD + CAD + CVD) did not demonstrate an interaction P value of
significance for the primary end points of cardiovascular death, MI, or ischemic stroke (P = .71), and
major bleeding (P = .31).
Compared with patients with PAD alone and following adjustment for baseline variables, a
stepwise increase in risk of the primary end point was observed with each additional diseased
vascular bed: PAD + CVD (aHR, 1.34; 95% CI, 1.15-1.57; P < .001), PAD + CAD (aHR, 1.65; 95% CI, 1.43-
1.91; P < .001), and PAD + CAD + CVD (aHR, 1.99; 95%CI, 1.69-2.34; P < .001). A comparable increase
in risk was observed for cardiovascular death and MI with each additional diseased vascular bed
JAMANetworkOpen | Cardiology Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease
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Table 1. Baseline Characteristics
Characteristic
No. (%)
P ValuePAD Only PAD + CAD PAD + CVD PAD + CAD + CVD
Patients 7804 (56.2) 2639 (19.0) 2049 (14.8) 1393 (10.0)
Age, median (IQR), y 65 (59-72) 66 (61-73) 67 (61-73) 68 (63-74) <.001
Women 2364 (30.3) 588 (22.3) 621 (30.3) 315 (22.6) <.001
Region
Asia 1002 (12.8) 201 (7.6) 292 (14.3) 107 (7.7)
<.001
Central/South America 1131 (14.5) 358 (13.6) 160 (7.8) 91 (6.5)
Europe 4525 (58.0) 1251 (47.4) 1135 (55.4) 587 (42.1)
North America 1146 (14.7) 829 (31.4) 462 (22.5) 608 (43.6)
Weight, median (IQR), kg 75 (65-86) 80 (69-91) 75 (65-86) 80 (70-90) <.001
Inclusion criteria for
randomization
<.001
Previous revascularization 4238 (54.3) 1541 (58.4) 1193 (58.2) 903 (64.8)
ABI or TBI criteria, mean
(SD)
3566 (45.7) 1098 (41.6) 856 (41.8) 490 (35.2)
ABI value 0.63 (0.16) 0.64 (0.14) 0.62 (0.14) 0.63 (0.13) .004
TBI value 0.52 (0.14) 0.54 (0.34) 0.48 (0.19) 0.53 (0.26) .49
Limb symptoms
Asymptomatic 1557 (20.0) 479 (18.2) 350 (17.1) 215 (15.4)
<.001
Mild or moderate
claudication
4168 (53.4) 1415 (53.6) 1093 (53.3) 734 (52.7)
Severe claudication 1678 (21.5) 638 (24.2) 525 (25.6) 387 (27.8)
Pain while at rest 217 (2.8) 70 (2.7) 47 (2.3) 44 (3.2)
Minor tissue loss 135 (1.7) 29 (1.1) 31 (1.5) 12 (0.9)
Major tissue loss 47 (0.6) 7 (0.3) 3 (0.1) 1 (0.1)
Major amputation above the
ankle
212 (2.7) 47 (1.8) 41 (2.0) 39 (2.8) .02
Minor amputation 414 (5.3) 83 (3.1) 74 (3.6) 34 (2.4) <.001
Medical history
Stroke 0 0 736 (35.9) 407 (29.2) NA
Transient ischemic attack 0 0 300 (14.6) 207 (14.9) NA
Myocardial infarction 0 1692 (64.1) 0 830 (59.6) NA
Carotid stenosis or carotid
revascularization
0 0 1423 (69.4) 1104 (79.3) NA
Diabetes, type 1 or 2 2724 (34.9) 1199 (45.4) 756 (36.9) 666 (47.8) <.001
Hypertension 5529 (70.8) 2304 (87.3) 1743 (85.1) 1281 (92.0) <.001
Hyperlipidemia 5241 (67.2) 2345 (88.9) 1607 (78.4) 1287 (92.4) <.001
Chronic kidney disease,
No./total No. (%)a
1558/7531 (20.7) 719/2564
(28.0)
545/1996
(27.3)
483/1358 (35.6) <.001
Tobacco use n = 7744 n = 2627 n = 2042 n = 1390 <.001
Current 2555 (33.0) 723 (27.5) 649 (31.8) 362 (26.0) <.001
Former 3365 (43.5) 1401 (53.3) 965 (47.3) 799 (57.5) <.001
Never 1824 (23.6) 503 (19.1) 428 (21.0) 229 (16.5) <.001
Medications
Aspirin 4802 (61.5) 2045 (77.5) 1344 (65.6) 1080 (77.5) <.001
Clopidogrel 2045 (26.2) 978 (37.1) 782 (38.2) 668 (48.0) <.001
DAPT 841 (10.8) 617 (23.4) 356 (17.4) 453 (32.5) <.001
Statin 5123 (65.6) 2299 (87.1) 1531 (74.7) 1228 (88.2) <.001
ACE inhibitor 2741 (35.1) 1318 (49.9) 872 (42.6) 704 (50.5) <.001
Angiotensin receptor
blocker
1850 (23.7) 705 (26.7) 571 (27.9) 362 (26.0) <.001
Cilostazol 1254 (16.1) 363 (13.8) 297 (14.5) 181 (13.0) .002
Abbreviations: ABI, ankle-brachial index; ACE,
angiotensin-converting enzyme; CAD, coronary artery
disease; CVD, cerebrovascular disease; DAPT, dual
antiplatelet therapy; IQR, interquartile range; NA, not
applicable; PAD, peripheral artery disease; TBI, toe-
brachial index.
a Chronic kidney disease was defined as estimated
glomerular filtration rate less than 60mL/min/1.73
m2.
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(Figure 2). With regard to key limb end points, the risk of acute limb ischemia requiring
hospitalization andmajor amputation was similar among all cohorts regardless of the presence of
polyvascular disease. The risk of lower-extremity revascularization increased in a stepwise fashion
with each additional diseased vascular bed: PAD + CAD (aHR, 1.17; 95% CI, 1.03-1.34; P = .01), PAD +
CVD (aHR, 1.17; 95% CI, 1.02-1.35; P = .02), and PAD + CAD + CVD (aHR, 1.34; 95% CI, 1.15-1.57;
P < .001). The risk of TIMI major bleeding was consistent among all cohorts (Figure 3).
Polyvascular disease was not associated with an increased risk of ALI (aHR for PAD + CVD, 0.91;
95%CI, 0.62-1.34, P = .63; PAD + CAD, 0.93; 95%CI, 0.64-1.34, P = .69; and PAD + CAD + CVD, 0.98;
95%CI, 0.63-1.53, P = .93), major amputation (aHR for PAD + CVD, 0.83; 95%CI, 0.54-1.27, P = .40;
PAD + CAD, 0.74; 95%CI, 0.47-1.16, P = .19; and PAD + CAD + CVD, 1.12; 95%CI, 0.69-1.80, P = .65), or
TIMImajor bleeding (aHR for PAD + CVD, 0.98; 0.66-1.44, P = .91; PAD + CAD, 1.04; 0.74-1.48, P = .81;
and PAD + CAD + CVD, 0.96; 95% CI, 0.62-1.51, P = .88).
Discussion
In this study of 13 885 patients with PAD after adjustment for significant baseline variables,
polyvascular disease (>1 diseased vascular bed at baseline) was associated with an increased risk of
MACEs, defined as cardiovascular death, MI, or stroke, in patients in whom the reference is
established isolated PAD. The risk of ALI requiring hospitalization andmajor amputation was similar
in patients with PAD with polyvascular disease compared with patients with PAD alone. The risk of
lower-extremity revascularization, however, was increased among patients with polyvascular
disease. The risk of the primary safety end point of TIMI major bleeding after adjustment was similar
in patients with polyvascular disease comparedwith thosewith PAD alone. These findings have both
mechanistically and clinically important implications.
To our knowledge, the effect of polyvascular disease on bothmajor adverse cardiac and limb
events has not been previously evaluated in a contemporary clinical trial of patients with
symptomatic PAD. Previous studies involving a large international registry of patients with stable
atherosclerotic disease (CAD, CVD, or PAD) have found the existence of polyvascular disease to
confer a heightened risk of ischemic events.3,15 Consistent with these findings, patients with PAD and
Table 2. Unadjusted Polyvascular Disease Outcomes: Efficacy and Safety
Outcome
PAD Only
(n = 7804) PAD + CAD (n = 2639) PAD + CVD (n = 2049) PAD + CAD + CVD (n = 1393)
Rate (Count)a
Rate
(Count)a HR (95% CI) P Valueb
Rate
(Count)a HR (95% CI) P Valueb
Rate
(Count)a HR (95% CI)
P
Valueb
Composite end
points
CV death, MI,
stroke
3.37 (639) 5.74 (357) 1.70 (1.50-1.94) <.001 4.78 (234) 1.42 (1.22-1.65) <.001 8.12 (261) 2.41 (2.09-2.78) <.001
Efficacy end points
CV death 1.70 (331) 2.48 (162) 1.46 (1.21-1.76) <.001 2.18 (111) 1.28 (1.03-1.59) .02 2.96 (102) 1.74 (1.39-2.17) <.001
MI 1.22 (232) 3.03 (190) 2.49 (2.06-3.02) <.001 2.06 (102) 1.70 (1.34-2.14) <.001 4.90 (159) 4.03 (3.30-4.94) <.001
Ischemic stroke 0.75 (144) 0.79 (51) 1.06 (0.77-1.45) .74 1.12 (56) 1.49 (1.09-2.03) .01 1.45 (49) 1.93 (1.40-2.67) <.001
ALI requiring
hospitalization
0.71 (136) 0.62 (40) 0.87 (0.61-1.24) .45 0.66 (33) 0.92 (0.63-1.35) .69 0.68 (23) 0.96 (0.61-1.49) .84
Major amputation 0.72 (138) 0.42 (27) 0.58 (0.38-0.88) .01 0.56 (28) 0.77 (0.51-1.16) .22 0.68 (23) 0.94 (0.61-1.46) .79
LER 4.82 (870) 6.03 (361) 1.25 (1.10-1.41) <.001 5.90 (274) 1.22 (1.07-1.40) .004 7.58 (233) 1.57 (1.35-1.81) <.001
Safety end points
TIMI major
bleeding
0.70 (118) 0.84 (46) 1.20 (0.86-1.69) .28 0.76 (33) 1.09 (0.74-1.60) .67 0.89 (25) 1.27 (0.83-1.96) .27
TIMI minor
bleeding
0.43 (73) 0.48 (26) 1.10 (0.70-1.72) .67 0.60 (26) 1.39 (0.89-2.17) .15 0.93 (26) 2.14 (1.36-3.34) .001
Abbreviations: ALI, acute limb ischemia; CAD, coronary artery disease; CV,
cardiovascular; CVD, cerebrovascular disease; HR, hazard ratio; LER, lower-extremity
revascularization; MI, myocardial infarction; PAD, peripheral artery disease; TIMI,
Thrombolysis in Myocardial Infarction.
a Event rates defined as number of events per 100 patient-years of follow-up.
b P values are from the log-rank test comparing the Kaplan-Meier rates across groups.
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polyvascular disease from the EUCLID trial demonstrated an incremental rise in MACE risk with each
additional diseased vascular territory. The risk of the individual components of cardiovascular death
andMI also rose in a stepwise fashion with each additional diseased vascular territory. The novelty of
the present analysis is the finding that polyvascular disease is independently associated with an
increase in lower-extremity revascularization. In addition, among the EUCLID trial population,
geographic location has been demonstrated to also affect the rate of lower-extremity
revascularization.16
In light of an observed increased risk of adverse events associated with polyvascular disease,
one would expect to detect a greater clinical benefit among these subpopulations owing to a greater
opportunity for treatment benefit; however, this outcomewas not the case in the present study. The
interpretation for this difference likely stems from the overall findings of the EUCLID trial, which
were neutral. Close examination of these previously published results demonstrates event rates and
times-to-event analyses for efficacy and safety end points to be similar among both ticagrelor and
clopidogrel cohorts.14
Our findings expand our knowledge of polyvascular disease in several ways. First, in the setting
of PAD, not all polyvascular disease is the same. Studies have previously evaluated outcomes
stratified according to the number of diseased vascular beds—0, 1, 2, or 3—with the coronary vascular
bed being the reference in all patients. In the present analysis, evaluation of all 4 phenotypes of
Figure 1. Outcomes for the Efficacy End Points
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cardiovascular disease among patients with PAD (defined as PAD alone, PAD + CAD, PAD + CVD, or
PAD + CAD + CVD) showed that the highest rates of ischemic events occurred in patients with PAD
+ CAD.
Figure 2. Major Adverse Cardiac Events According to Polyvascular Disease Phenotype
P Value
Favors
Decreased Risk
Favors
Increased RiskOutcome
Rate 
(No. of Events)
Adjusted HR 
(95% CI)
0.5 31 2
Adjusted HR (95% CI)
Primary end point
4.78 (234) <.001PAD + CVD
5.74 (357)
1.34 (1.15-1.57)
<.001PAD + CAD
8.12 (261)
1.65 (1.43-1.91)
<.001PAD + CAD + CVD 1.99 (1.69-2.34)
Cardiovascular death
2.18 (111) .01PAD + CVD
2.48 (162)
1.34 (1.06-1.67)
<.001PAD + CAD
2.96 (102)
1.64 (1.33-2.01)
<.001PAD + CAD + CVD 1.80 (1.40-2.30)
Myocardial infarction
2.06 (102) .01PAD + CVD
3.03 (190)
1.36 (1.06-1.67)
<.001PAD + CAD
4.90 (159)
2.03 (1.65-2.49)
<.001PAD + CAD + CVD 2.57 (2.06-3.21)
Ischemic stroke
1.12 (56) .04PAD + CVD
0.79 (51)
1.38 (1.01-1.89)
<.001PAD + CAD
1.45 (49)
1.00 (0.72-1.40)
.01PAD + CAD + CVD 1.71 (1.21-2.42)
Adjusted rates presented as events per 100 patient-years. Reference group was patients
with peripheral artery disease (PAD) alone. The primary end point (composite of
cardiovascular death, myocardial infarction, and ischemic stroke) was adjusted for age,
weight, sex, estimated glomerular filtration rate (eGFR), baseline ankle-brachial index
(ABI), randomized treatment, sex, inclusion criteria, geographic region, critical limb
ischemia, diabetes (type 1 or 2), statin use before randomization, smoking status, prior
major amputation, and prior minor amputation. Cardiovascular death was adjusted for
age, weight, eGFR, baseline ABI, randomized treatment, sex, geographic region, critical
limb ischemia, diabetes, use of statins before randomization, and prior minor
amputation. Myocardial infarction was adjusted for age, eGFR, baseline ABI, randomized
treatment, inclusion criteria, geographic region, diabetes, smoking status, and prior
minor amputation. Ischemic stroke was adjusted for age, baseline ABI, randomized
treatment, geographic region, diabetes, smoking status, and prior minor amputation.
CAD indicates coronary artery disease; CVD, cerebrovascular disease; and HR,
hazard ratio.
Figure 3. Major Adverse Limb Events and Safety Events According to Polyvascular Disease Phenotype
P Value
Favors
Decreased Risk
Favors
Increased RiskOutcome
Rate 
(No. of Events)
Adjusted HR 
(95% CI)
0.5 31 2
Adjusted HR (95% CI)
Acute limb ischemia
0.66 (33) .63PAD + CVD
0.62 (40)
0.91 (0.62-1.34)
.69PAD + CAD
0.68 (22)
0.93 (0.64-1.34)
.93PAD + CAD + CVD 0.98 (0.63-1.53)
Major amputation
0.56 (28) .40PAD + CVD
0.42 (27)
0.83 (0.54-1.27)
.19PAD + CAD
0.68 (23)
0.74 (0.47-1.16)
.65PAD + CAD + CVD 1.12 (0.69-1.80)
Lower-extremity 
revascularization
5.90 (274) .02PAD + CVD
6.03 (361)
1.17 (1.02-1.35)
.01PAD + CAD
7.58 (233)
1.17 (1.03-1.34)
<.001PAD + CAD + CVD 1.34 (1.15-1.57)
TIMI major bleed
0.76 (33) .91PAD + CVD
0.84 (46)
0.98 (0.66-1.44)
.81PAD + CAD
0.89 (25)
1.04 (0.74-1.48)
.88PAD + CAD + CVD 0.96 (0.62-1.51)
Adjusted rates presented as events per 100 patient-
years. Reference group was patients with peripheral
artery disease (PAD) alone. Acute limb ischemia was
adjusted for baseline ankle-brachial index (ABI),
randomized treatment, inclusion criteria, use of statins
before randomization, and use of angiotensin receptor
blockers before randomization. Lower-extremity
revascularization was adjusted for baseline ABI,
estimated glomerular filtration rate, inclusion criteria,
diabetes (type 1 or 2), use of aspirin before
randomization, use of clopidogrel before
randomization, and smoking status. Amputation was
adjusted for weight, baseline ABI, inclusion criteria,
critical limb ischemia, diabetes, use of statins before
randomization, prior major amputation, and prior
minor amputation. Major bleeding was adjusted for
age, randomized treatment, and geographic region.
Minor bleeding was adjusted for age, baseline ABI,
inclusion criteria, sex, randomized treatment, and
geographic region. CAD indicates coronary artery
disease; CVD, cerebrovascular disease; HR, hazard
ratio; and TIMI, Thrombolysis in Myocardial Infarction.
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Second, among patients with polyvascular disease, the increase in ischemic events is related to
the polyvascular disease phenotype. For example, patients with PAD + CAD experienced the highest
rates of cardiovascular death andMI, while patients with PAD + CVD experienced the highest rates of
ischemic stroke. The addition of CAD or CVDwas not associatedwith a higher risk of the adverse limb
events of ALI or major amputation; however, CAD and CVDwere linked to a heightened risk of
lower-extremity revascularization. These data highlight the increased risk of CAD and CVD among
patients with PAD and the need to identify potent preventive antithrombotic therapies.
In addition, we evaluated the risk of major bleeding in patients with polyvascular disease on a
background of PAD. Evaluation of a large registry of patients presenting with acute coronary
syndromes found polyvascular disease to be associated with increased rates of blood transfusion
among patients who did not undergo coronary artery bypass grafting.2 In our analysis, there was no
clear evidence that polyvascular disease conferred an increased risk of major bleeding among
patients with PAD.
Limitations
The present study has limitations. First, it is a post hoc secondary analysis of subgroups of the overall
EUCLID trial; as such, results are considered hypothesis generating, and caution should be usedwhen
interpreting all findings. Second, themedian follow-up period was 36months; therefore, any
potential benefit or risk of ticagrelor therapy in a stable outpatient PAD population beyond this time
frame is uncertain.
Conclusions
In EUCLID, a randomized trial of ticagrelor vs clopidogrel in patients with symptomatic PAD,
polyvascular disease was present in 43.8% of the study population. Compared with patients with
PAD alone, the risk of MACEs and lower-extremity revascularization increased with atherosclerosis
across multiple vascular territories. Polyvascular disease, however, was not associated with an
increased risk of TIMI major bleeding compared with patients with PAD alone. These data highlight
the increased risk of CAD and CVD among patients with PAD and the need to identify potent
preventive antithrombotic therapies.
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